SINAGRA, Gianfranco
 Distribuzione geografica
Continente #
NA - Nord America 2.302
AS - Asia 1.780
EU - Europa 942
SA - Sud America 393
AF - Africa 48
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.472
Nazione #
US - Stati Uniti d'America 2.225
SG - Singapore 654
CN - Cina 463
BR - Brasile 336
HK - Hong Kong 258
IT - Italia 208
DE - Germania 162
VN - Vietnam 135
FI - Finlandia 108
FR - Francia 84
RU - Federazione Russa 76
UA - Ucraina 76
GB - Regno Unito 75
TR - Turchia 63
IN - India 56
BD - Bangladesh 46
CA - Canada 41
IE - Irlanda 36
JP - Giappone 24
MX - Messico 23
PL - Polonia 21
ZA - Sudafrica 17
IQ - Iraq 16
AR - Argentina 15
SE - Svezia 15
ES - Italia 14
AT - Austria 13
NL - Olanda 13
SA - Arabia Saudita 11
CZ - Repubblica Ceca 10
MA - Marocco 10
EC - Ecuador 8
LT - Lituania 8
KE - Kenya 7
PK - Pakistan 7
CL - Cile 6
CO - Colombia 6
PY - Paraguay 6
UZ - Uzbekistan 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
JO - Giordania 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BO - Bolivia 4
CH - Svizzera 4
PH - Filippine 4
BE - Belgio 3
EG - Egitto 3
ID - Indonesia 3
JM - Giamaica 3
LK - Sri Lanka 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PE - Perù 3
SC - Seychelles 3
TN - Tunisia 3
AM - Armenia 2
CR - Costa Rica 2
GR - Grecia 2
IL - Israele 2
NP - Nepal 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AU - Australia 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MT - Malta 1
MU - Mauritius 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
RO - Romania 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 5.472
Città #
Ashburn 332
Singapore 326
Hong Kong 257
San Jose 193
Beijing 146
The Dalles 115
Fairfield 110
New York 101
Los Angeles 81
Helsinki 78
Dallas 68
Woodbridge 66
Chandler 57
Jacksonville 56
Lauterbourg 56
Munich 55
Istanbul 54
Seattle 54
Ho Chi Minh City 52
Wilmington 44
Houston 40
Princeton 40
São Paulo 39
Cambridge 37
Dublin 36
Milan 33
Hanoi 31
Orem 31
Buffalo 29
Romola 27
Redondo Beach 26
Ann Arbor 25
Shanghai 25
San Francisco 24
Moscow 23
Chennai 21
Tokyo 20
Chicago 19
Montreal 19
Brescia 18
Santa Clara 18
Turku 18
Warsaw 18
Washington 18
Frankfurt am Main 17
Council Bluffs 16
Nanjing 16
London 15
Guangzhou 14
Nuremberg 14
Atlanta 13
Boston 13
Rome 13
Poplar 12
Des Moines 11
Brooklyn 10
Dearborn 10
Denver 10
Hangzhou 10
Johannesburg 10
Lappeenranta 10
Stockholm 10
Belo Horizonte 9
Brno 9
City of London 9
Toronto 9
Brasília 8
Dhaka 8
Haiphong 8
Hebei 8
Rio de Janeiro 8
San Diego 8
Vienna 8
Amsterdam 7
Boydton 7
Düsseldorf 7
Phoenix 7
Salvador 7
Ankara 6
Curitiba 6
Da Nang 6
Mumbai 6
Novara 6
Paris 6
Querétaro 6
Baghdad 5
Charlotte 5
Hải Dương 5
Jinan 5
Lahore 5
Manchester 5
Mexico City 5
Nairobi 5
Pune 5
Salt Lake City 5
Sete Lagoas 5
Shenyang 5
Tashkent 5
Amman 4
Baku 4
Totale 3.402
Nome #
Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database 159
Heart failure and anemia: Effects on prognostic variables 148
Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias 145
Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction 144
Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group 141
The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study 133
Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation 127
ANMCO / FADOI / SIAARTI / SIC / SIMG / SIMI / SIMEU Consensus Document: The clinical-diagnostic and therapeutic pathway of the patient with acute heart failure from home to discharge from the Emergency Room / Emergency Department-Acceptance 118
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 117
The prognostic value of serial troponin measurements in patients admitted for COVID-19 114
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials] 105
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 104
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 104
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal damage] 104
[Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part I: From cardiovascular risk factors to the mechanisms of cardio-renal syndrome] 100
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 98
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach 97
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 94
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 94
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice] 93
[Palliative inotrope therapy in advanced heart failure: organization and management] 93
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 92
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 89
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 88
[2022 Update on myocarditis and pericarditis following COVID-19 vaccination. Expert Opinion of the Italian Society of Cardiology] 87
[Transcatheter devices for chronic heart failure: state of the art] 85
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 83
[Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology] 82
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 82
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 82
The chronic heart failure evolutions: Different fates and routes 82
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 81
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 81
Atrial signal amplitude predicts atrial high-rate episodes in implantable cardioverter defibrillator patients: Insights from a large database of remote monitoring trasmissions 79
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 79
[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine] 77
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 74
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 73
Impact of malnutrition in patients with severe heart failure 72
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 69
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 69
Apoptosis, a useful marker in the management of hot-phase cardiomyopathy? 69
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era 69
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 67
[Italian Society of Cardiology (SIC) Expert consensus document: Post-acute cardiovascular sequelae of SARS-CoV-2 infection] 66
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration 64
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 63
Palliative care in the cardiac setting: A consensus document of the Italian Society of Cardiology (SIC) and Italian Society of Palliative Care (SICP) Joint Working Group 61
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 61
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 60
The impact of UEFA Euro 2020 football championship on Takotsubo Syndrome: Results of a multicenter national registry 60
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 59
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 59
Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension 58
Management of hypertrophic cardiomyopathy 58
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 58
Effects of the COVID-19 pandemic on the formation of fellows in training in cardiology 53
ECG/echo indexes in the diagnostic approach to amyloid cardiomyopathy: A head-to-head comparison from the AC-TIVE study 53
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish National Diabetes Registries 53
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 52
Correction to: SARS‑CoV‑2, myocardial injury and inflammation: insights from a large clinical and autopsy study 51
Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry 48
Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 46
Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE-TR registry 45
Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype 45
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 42
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology 41
SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study 40
Totale 5.539
Categoria #
all - tutte 33.184
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.184


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 0 0 0 0 31 16 15
2021/2022123 6 5 5 9 1 5 1 9 7 16 19 40
2022/2023238 37 23 4 4 11 52 2 23 51 3 14 14
2023/2024637 35 13 68 60 43 111 39 23 111 25 26 83
2024/20251.317 15 12 43 144 97 100 173 69 120 91 248 205
2025/20262.608 270 387 205 390 341 213 337 127 195 143 0 0
Totale 5.539